These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539 [TBL] [Abstract][Full Text] [Related]
6. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Morgan NY; English S; Chen W; Chernomordik V; Russo A; Smith PD; Gandjbakhche A Acad Radiol; 2005 Mar; 12(3):313-23. PubMed ID: 15766692 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690 [TBL] [Abstract][Full Text] [Related]
8. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of cytokine-induced killer cells against human lung cancer. Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691 [TBL] [Abstract][Full Text] [Related]
10. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts. Dannemann BR; Morris VA; Araujo FG; Remington JS J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453 [TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. Sutlu T; Alici E J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820 [TBL] [Abstract][Full Text] [Related]
12. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871 [TBL] [Abstract][Full Text] [Related]
13. Novel approaches using natural killer cells in cancer therapy. Suck G Semin Cancer Biol; 2006 Oct; 16(5):412-8. PubMed ID: 16914327 [TBL] [Abstract][Full Text] [Related]
14. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy. Zhang J; Sun R; Wei H; Zhang J; Tian Z Oncol Rep; 2004 May; 11(5):1097-106. PubMed ID: 15069553 [TBL] [Abstract][Full Text] [Related]
15. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone. Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882 [TBL] [Abstract][Full Text] [Related]
16. The biology of human natural killer cells. Whiteside TL; Herberman RB Ann Ist Super Sanita; 1990; 26(3-4):335-48. PubMed ID: 2091502 [TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function. Lin SJ; Kuo ML Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772 [TBL] [Abstract][Full Text] [Related]
18. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin. Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416 [TBL] [Abstract][Full Text] [Related]
19. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934 [TBL] [Abstract][Full Text] [Related]
20. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]